Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat vs Darbepoetin for Renal Oxygenation in Diabetic Nephropathy
NCT05810311Phase 2Not yet recruiting
- Sponsor
- Region Stockholm
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of roxadustat in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Region Stockholm. Primary endpoint: Change in kidney oxygenation levels at 24 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
roxadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT05810311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810311.